208 related articles for article (PubMed ID: 37324454)
21. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others.
Bupathi M; Wu C
J Gastrointest Oncol; 2016 Oct; 7(5):713-720. PubMed ID: 27747085
[TBL] [Abstract][Full Text] [Related]
23. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.
Fitzsimmons TS; Singh N; Walker TDJ; Newton C; Evans DGR; Crosbie EJ; Ryan NAJ
Front Med (Lausanne); 2023; 10():1192762. PubMed ID: 37250628
[TBL] [Abstract][Full Text] [Related]
26. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
[TBL] [Abstract][Full Text] [Related]
27. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
28. Molecular Signatures of
Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
[TBL] [Abstract][Full Text] [Related]
30. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
31. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
32. Pathogenic Insights into DNA Mismatch Repair (MMR) Genes-Proteins and Microsatellite Instability: Focus on Adrenocortical Carcinoma and Beyond.
Carsote M; Turturea IF; Turturea MR; Valea A; Nistor C; Gheorghisan-Galateanu AA
Diagnostics (Basel); 2023 May; 13(11):. PubMed ID: 37296718
[TBL] [Abstract][Full Text] [Related]
33. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
[TBL] [Abstract][Full Text] [Related]
34. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
35. The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
Stokkel LE; Stokkel MPM; Donswijk ML; Lahaye MJ; Bekers EM; van Rhijn BWG; Mertens LS
Clin Genitourin Cancer; 2021 Oct; 19(5):373-380. PubMed ID: 33858788
[TBL] [Abstract][Full Text] [Related]
36. Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers.
Mohanty SK; Mishra SK; Amin MB; Agaimy A; Fuchs F
Adv Anat Pathol; 2023 May; 30(3):174-194. PubMed ID: 37037418
[TBL] [Abstract][Full Text] [Related]
37. KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Cinausero M; Laprovitera N; De Maglio G; Gerratana L; Riefolo M; Macerelli M; Fiorentino M; Porcellini E; Buoro V; Gelsomino F; Squadrilli A; Fasola G; Negrini M; Tiseo M; Ferracin M; Ardizzoni A
Ther Adv Med Oncol; 2019; 11():1758835919885540. PubMed ID: 31798692
[TBL] [Abstract][Full Text] [Related]
38. The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer.
Liu L; Li F; Zhao J; Zhuo X; Lai J; Wang J; Jiang F; Xu W; Luan F; Lin X; Yang S; Fu G
J Cancer; 2023; 14(6):952-965. PubMed ID: 37151388
[No Abstract] [Full Text] [Related]
39. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
40. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
